Evidence map›Paper›PMID 35726221›Full record

ArticleJournal of oncology2022

Multifactorial Analysis of Clinical Prognosis of Liver Metastasis and Vascular Intervention Combined with Ablation in Colorectal Cancer.

WenJi Lin, CongHui Zhu, JiaDi Yao, YuHuang Liu, HuiYu Lin, Yan Liu

RetractedOpen access · hybridAbstract readRetracted Publication
In one paragraph

Article in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

WenJi LinDepartment of Interventional, Quanzhou First Hospital Affiliated of Fujian Medical University, Quanzhou 362000, Fujian, China.
CongHui ZhuDepartment of Interventional, Quanzhou First Hospital Affiliated of Fujian Medical University, Quanzhou 362000, Fujian, China.
JiaDi YaoDepartment of Interventional, Quanzhou First Hospital Affiliated of Fujian Medical University, Quanzhou 362000, Fujian, China.
YuHuang LiuDepartment of Interventional, Quanzhou First Hospital Affiliated of Fujian Medical University, Quanzhou 362000, Fujian, China.
HuiYu LinDepartment of Imaging, Quanzhou First Hospital Affiliated of Fujian Medical University, Quanzhou 362000, Fujian, China.
Yan LiuDepartment of Gastrointestinal Surgery, Quanzhou First Hospital Affiliated of Fujian Medical University, Quanzhou 362000, Fujian, China.ORCID https://orcid.org/0000-0003-2127-0758
Fujian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer is one of the leading causes of deaths in China. The initial stages of colorectal cancer can be treated by surgery, radiation, and chemotherapy. However, in the advanced stages, it warrants an application of multimodality treatment. With advances in the medical field, there are applications of new modality of treatment that could possibly provide the appropriate treatment for the advanced stage tumours. The first site of metastasis after colorectal cancer is the liver and the conventional treatment to cure the metastatic lesion involves the administration of chemotherapy. With further advancement, chemotherapy has been directly administered at the thorough transarterial chemoembolization (TACE) which is a vascular intervention. With further advancement, the nonvascular intervention, such as radiofrequency ablations (RFAs), has been administered to the patients. A large amount of data support the use of vascular intervention (TACE) with ablation for hepatic carcinoma; there is no sufficient literature to support the application of the modality in the metastatic liver lesion. In this prospective observational study, we have enrolled 80 patients with metastatic liver lesion from the adenocarcinoma of colon or rectum, treated the patients with a combination of the TACE and ablation therapy, and followed up the patients for a period of 3 years. A multivariate analysis of the various factors that influence the prognosis and outcome has been studied and it has been concluded that the combination therapy is medically beneficial for individuals with aggressive liver lesions, improving overall as well as progression-free life span.

Identifiers

PMID35726221
PMCPMC9206548
OpenAlexW4285740236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.